Skip to main content
Erschienen in: Molecular Neurodegeneration 1/2013

Open Access 01.09.2013 | Poster presentation

Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1

verfasst von: Sarah Pickles, Laurie Destroismaisons, Sarah Peyrard, Sarah Cadot, Guy Rouleau, Robert Brown Jr., Jean-Pierre Julien, Nathalie Arbour, Christine Vande Velde

Erschienen in: Molecular Neurodegeneration | Sonderheft 1/2013

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Background

Amyotrophic lateral sclerosis (ALS) is a late onset neurodegenerative disorder characterized by the loss of motor neurons resulting in a progressive paralysis that ultimately leads to death. Although the majority of cases are sporadic, some cases are caused by genetic mutation in Superoxide Dismutase 1 (SOD1) where mutations yield misfolded protein leading to an unknown toxic gain of function. Mitochondria have long been considered a target of mutant SOD1 toxicity. Mitochondrial morphological abnormalities are an early feature in the pathology of ALS in both patients and animal models and various aspects of mitochondrial dysfunction have been reported in ALS models although no consensus exists. How this primarily cytosolic protein can affect mitochondria remains to be established. Using antibodies specific for misfolded SOD1, we have previously shown misfolded SOD1 to be associated with the outer membrane of spinal cord mitochondria from ALS animal models. We hypothesize that the mitochondrial association of misfolded SOD1 negatively impacts key aspects of mitochondrial function.

Materials and methods

Using a novel flow cytometric assay, spinal cord mitochondria isolated from rodent models overexpressing mutant SOD1 were immunolabelled with an antibody targeted to misfolded SOD1 (B8H10), and fluorescent indicator probes were used to assess damage tracking with the presence of the misfolded protein on the mitochondrial surface.

Results

Using two antibodies targeted to misfolded SOD1, B8H10 and C4F6, we find selectivity for the B8H10-reactive misfolded SOD1 for spinal cord mitochondria isolated from SOD1G93A rats. In contrast, C4F6-reactive SOD1 is not mitochondrially associated. Here, we report an age-dependent deposition of B8H10-reactive SOD1 on spinal cord mitochondria in two different mutant SOD1 models. The presence of misfolded SOD1 on the mitochondrial surface appeared before other markers of pathology including weight loss, gliosis and significant loss of motor neurons. Mitochondria labelling positively for B8H10-reactive SOD1 had increased mitochondrial volume, produced excess superoxide, and had increased exposure of the toxic BH3 domain of Bcl-2. Lastly, B8H10-reactive misfolded SOD1 was found in lysates and mitochondrial fractions of lymphoblasts derived from ALS patients carrying SOD1 mutations, but not in controls.

Conclusions

This assay identified dysfunction of a mitochondrial subpopulation coated with B8H10-reactive SOD1 which appeared prior to classic markers of pathology, and thus may be especially relevant to disease onset. That B8H10-reactive misfolded was also present in patient lymphoblasts as well as animal models demonstrates the universal nature of this misfolded conformer. How misfolded evokes these damages to mitochondria is presently under evaluation.

Acknowledgements

This work was supported by the Canadian Institutes of Health Research, ALS Society of Canada, Frick Foundation, CHUM Foundation, and Fonds de la Recherche en Santé du Québec.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​ ) applies to the data made available in this article, unless otherwise stated.
Metadaten
Titel
Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1
verfasst von
Sarah Pickles
Laurie Destroismaisons
Sarah Peyrard
Sarah Cadot
Guy Rouleau
Robert Brown Jr.
Jean-Pierre Julien
Nathalie Arbour
Christine Vande Velde
Publikationsdatum
01.09.2013
Verlag
BioMed Central
Erschienen in
Molecular Neurodegeneration / Ausgabe Sonderheft 1/2013
Elektronische ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-8-S1-P70

Weitere Artikel der Sonderheft 1/2013

Molecular Neurodegeneration 1/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.